Saturday 17 October 2026
Export VRAX’s income statement to Excel — free account
Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
1.45
0.17
−10.49%
Follow VRAX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
6.44 | 4.23 | 3.59 | 9.35 | 0.02 | 0.02 | 0.02 |
Receivables |
0.03 | 0.03 | 0.22 | — | — | 0.00 | 0.00 |
Inventory |
0.00 | 0.09 | 0.06 | — | 0.02 | 0.02 | 0.02 |
Total current assets |
6.83 | 4.89 | 4.38 | 9.63 | 0.05 | 0.04 | 0.04 |
Property, Plant, Equpment (Net) |
1.17 | 1.23 | 0.90 | — | — | — | — |
Goodwill and Intangible Assets (Total) |
— | — | — | 0.18 | — | — | — |
Total non-current assets |
1.50 | 1.53 | 1.10 | 0.18 | — | — | — |
Total Assets |
8.32 | 6.43 | 5.48 | 9.81 | 0.05 | 0.04 | 0.04 |
Notes Payable |
— | — | — | 0.15 | — | — | — |
Accounts Payable |
0.58 | 0.59 | 0.12 | 0.72 | 1.24 | 0.50 | 0.21 |
Current Part of Debt |
0.03 | 0.03 | — | 0.15 | 0.00 | 0.18 | 0.76 |
Current Revenue (Deferred) |
— | — | — | 0.04 | — | — | — |
Total current liabilities |
0.69 | 0.67 | 0.17 | 0.91 | 1.25 | 0.87 | 0.87 |
Total non-current liabilities |
0.30 | 0.29 | 0.18 | — | — | — | — |
Total liabilities |
0.99 | 0.96 | 0.35 | 0.91 | 1.25 | 0.87 | 0.87 |
Common Stock (Net) |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(29.61) | (24.59) | (18.53) | (11.79) | (6.34) | (4.63) | (4.63) |
Shareholders Equity (Other) |
37.49 | 30.17 | 23.89 | 20.92 | 5.36 | 3.98 | — |
Common Equity (Total) |
7.33 | 5.46 | 5.14 | 8.90 | (1.20) | (0.83) | (4.63) |
Shareholders Equity (Total) |
7.33 | 5.46 | 5.14 | 8.90 | (1.20) | (0.83) | (0.83) |
Shareholders Equity and Liabilities (Total) |
8.32 | 6.43 | 5.48 | 9.81 | 0.05 | 0.04 | 0.04 |
Shares (Common) |
0.58 | 0.17 | 0.10 | 0.06 | 0.04 | 0.04 | — |
Shareholders Equity (Tangible) |
7.33 | 5.46 | 5.14 | 8.73 | (1.20) | (0.83) | (0.83) |
Net Debt |
(6.41) | (4.20) | (3.59) | (9.21) | (0.02) | 0.16 | 0.74 |
Total Debt |
0.03 | 0.03 | — | 0.15 | 0.00 | 0.18 | 0.76 |
In millions of $ except per-share values · columns are period end dates